公开(公告)号：US08609851B2

公开(公告)日：2013-12-17

申请号：US13126907

申请日：2009-10-27

Applicant: Shangjin Yang ,  Jianhui Yan ,  Ligang Wang ,  Xingna Guo ,  Shubin Li ,  Guoqiang Wu ,  Ruiya Zuo ,  Xin Huang ,  Hongtao Wang ,  Lingling Wang ,  Wenjuan Huang ,  Huigang Lu ,  Ke Feng ,  Fang Li ,  Huimin He ,  Yu Liu

Inventor： Shangjin Yang ,  Jianhui Yan ,  Ligang Wang ,  Xingna Guo ,  Shubin Li ,  Guoqiang Wu ,  Ruiya Zuo ,  Xin Huang ,  Hongtao Wang ,  Lingling Wang ,  Wenjuan Huang ,  Huigang Lu ,  Ke Feng ,  Fang Li ,  Huimin He ,  Yu Liu

IPC: C07D401/00

CPC classification number: C07D401/04 ,  C07D213/60 ,  C07D213/61 ,  C07D213/73

Abstract: The present invention discloses a nitropyridinyl ethyleneimine compound as shown in the formula I and a preparation method of the same, as well as use of the compound in manufacture of a prodrug and in manufacture of a drug for treating a tumor.

公开(公告)号：US20130323167A1

公开(公告)日：2013-12-05

申请号：US13880608

申请日：2011-10-20

Applicant: Bert Vogelstein ,  Yuan Qiao ,  Xin Huang ,  Kenneth Kinzler ,  Shibin Zhou ,  Luis Diaz

Inventor： Bert Vogelstein ,  Yuan Qiao ,  Xin Huang ,  Kenneth Kinzler ,  Shibin Zhou ,  Luis Diaz

IPC: A61K51/10

CPC classification number: A61K51/1045 ,  A61K9/1271 ,  A61K39/395 ,  A61K45/06 ,  A61K51/1009 ,  C07K16/2887 ,  C07K16/40 ,  A61K2300/00

Abstract: Several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. Exemplary vascular-active agents include a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents.

Abstract translation: 能够诱导与炎症过程中观察到的血管反应类似的几种药物增强纳米颗粒在肿瘤中的积累。 示例性的血管活性剂包括细菌，促炎细胞因子和微管不稳定药物。 与单独的纳米颗粒相比，这样的药物可以将放射性的肿瘤与血液的比例增加20倍以上。 此外，血管活性剂显着改善了含有放射性同位素或化学治疗剂的纳米颗粒的治疗效果。

公开(公告)号：US08513067B2

公开(公告)日：2013-08-20

申请号：US13266791

申请日：2011-07-15

Applicant: Ru Huang ,  Jing Zhuge ,  Jiewen Fan ,  Yujie Ai ,  Runsheng Wang ,  Xin Huang

Inventor： Ru Huang ,  Jing Zhuge ,  Jiewen Fan ,  Yujie Ai ,  Runsheng Wang ,  Xin Huang

IPC: H01L21/84

CPC classification number: H01L29/66439 ,  B82Y10/00 ,  H01L29/775

Abstract: The invention discloses a fabrication method for a surrounding gate silicon nanowire transistor with air as spacers. The method comprises: performing isolation, and depositing a material A which has a higher etch selectivity ratio with respect to Si; performing photolithography to define a Fin hard mask; etching the material A to form the Fin hard mask; performing source and drain implantation; performing photolithography to define a channel region and large source/drain regions; forming the Si Fin and the large source/drains; removing the hard mask of the material A; forming a nanowire; etching the SiO2 to form a floating nanowire; forming a gate oxide layer; depositing a polysilicon; performing polysilicon injection; performing annealing to activate dopants; etching the polysilicon; depositing SiN; performing photolithography to define a gate pattern; etching the SiN and the polysilicon to form the gate pattern; separating the gate and the source/drain with a space in between filled with air; depositing SiO2 to form air sidewalls; performing annealing to densify the SiO2 layer; using subsequent processes to complete the device fabrication. The invention is compatible with the CMOS process flow. The introduction of the air sidewalls can effectively reduce the parasitic capacitance of the device, and improve the transient response of the device, so that the method is applicable for a logic circuit with high performance.

Abstract translation: 本发明公开了一种具有空气作为间隔物的周围栅极硅纳米线晶体管的制造方法。 该方法包括：执行隔离和沉积相对于Si具有较高蚀刻选择比的材料A; 执行光刻以限定Fin硬掩模; 蚀刻材料A以形成Fin硬掩模; 进行源极和漏极植入; 执行光刻以限定沟道区和大的源极/漏极区; 形成Si Fin和大源/排水; 去除材料A的硬掩模; 形成纳米线; 蚀刻SiO 2以形成浮动的纳米线; 形成栅氧化层; 沉积多晶硅; 执行多晶硅注入; 执行退火以激活掺杂剂; 蚀刻多晶硅; 沉积SiN; 执行光刻以限定栅极图案; 蚀刻SiN和多晶硅以形成栅极图案; 分离门和源/排水管之间的空间填充空气之间; 沉积SiO 2以形成空气侧壁; 进行退火以使SiO 2层致密化; 使用后续过程来完成器件制造。 本发明与CMOS工艺流程兼容。 空气侧壁的引入可以有效降低器件的寄生电容，提高器件的瞬态响应，使其适用于具有高性能的逻辑电路。

公开(公告)号：US20120220645A1

公开(公告)日：2012-08-30

申请号：US13407165

申请日：2012-02-28

Applicant: Susanne M. Gollin ,  Rahul Atul Parikh ,  Xin Huang

Inventor： Susanne M. Gollin ,  Rahul Atul Parikh ,  Xin Huang

IPC: A61K31/7088 ,  G01N33/566 ,  C12Q1/68 ,  G01N21/64 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K31/7105 ,  A61K45/06 ,  C12Q1/6841 ,  C12Q2600/106 ,  G01N33/57407 ,  G01N2333/91215 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.

公开(公告)号：US20120201121A1

公开(公告)日：2012-08-09

申请号：US13449967

申请日：2012-04-18

Applicant: Xin HUANG ,  Dingzhang DAI ,  Hongwei WANG ,  Fangfu GUO

Inventor： Xin HUANG ,  Dingzhang DAI ,  Hongwei WANG ,  Fangfu GUO

IPC: H04L12/24

CPC classification number: H04L1/1825 ,  H04L1/0015 ,  H04L1/1883

Abstract: An embodiment of the present invention discloses a high speed uplink packet access adaptive retransmission method and apparatus. The method includes: obtaining a resource limitation state; performing adjustment decision according to the resource limitation state and a current target number of retransmissions of a UE; and adjusting the target number of retransmissions of the UE between a preset large target number of retransmissions and a preset small target number of retransmissions, where the large target number of retransmissions is greater than the small target number of retransmissions. The utilization rate of resources may be effectively improved.

Abstract translation: 本发明的实施例公开了一种高速上行分组接入自适应重传方法和装置。 该方法包括：获取资源限制状态; 根据资源限制状态和UE的当前目标重传次数进行调整决定; 以及在预设的大目标重发次数与预定的小目标重发次数之间调整所述UE的目标重传次数，其中所述大目标重发次数大于所述小目标重传次数。 资源利用率可以有效提高。

公开(公告)号：US20120195889A1

公开(公告)日：2012-08-02

申请号：US13372824

申请日：2012-02-14

Applicant: Shirin K. Ford ,  Edwin A. Clark ,  Xin Huang

Inventor： Shirin K. Ford ,  Edwin A. Clark ,  Xin Huang

IPC: A61K39/395 ,  C12Q1/68 ,  A61P35/00 ,  C40B30/04

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  G01N33/57419 ,  G01N2333/485 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2800/52

Abstract: EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Abstract translation: EGFR生物标志物可用于预测将对治疗癌症治疗的治疗反应的哺乳动物的可能性的方法，其包括施用EGFR调节剂，其中所述方法包括（a）在哺乳动物中测量至少一种选自上皮蛋白的生物标志物 （b）将生物样品从哺乳动物暴露于EGFR调节剂，和（c）在暴露步骤（b）之后，在生物样品中测量至少一种生物标志物的水平，其中增加 与步骤（a）中测量的至少一种生物标志物的水平相比，在步骤（c）中测量的至少一种生物标志物的水平表明哺乳动物对治疗癌症的方法治疗反应的可能性增加。

公开(公告)号：US20110319378A1

公开(公告)日：2011-12-29

申请号：US13153345

申请日：2011-06-03

Applicant: Michael David BARTBERGER ,  Ana GONZALEZ BUENROSTRO ,  Hilary Plake BECK ,  Xiaoqi CHEN ,  Richard Victor CONNORS ,  Jeffrey DEIGNAN ,  Jason DUQUETTE ,  John EKSTEROWICZ ,  Benjamin FISHER ,  Brian Matthew FOX ,  Jiasheng FU ,  Zice FU ,  Felix GONZALEZ LOPEZ DE TURISO ,  Michael GRIBBLE, JR. ,  Darin James GUSTIN ,  Julie Anne HEATH ,  Xin HUANG ,  Xianyun JIAO ,  Michael G. JOHNSON ,  Frank KAYSER ,  David John KOPECKY ,  Sujen LAI ,  Yihong LI ,  Zhihong LI ,  Jiwen LIU ,  Jonathan Dante LOW ,  Brian Stuart LUCAS ,  Zhihua MA ,  Lawrence McGEE ,  Joel McINTOSH ,  Dustin McMINN ,  Julio Cesar MEDINA ,  Jeffrey Thomas MIHALIC ,  Steven Howard Olson ,  Yosup REW ,  Philip Marley ROVETO ,  Daqing SUN ,  Xiaodong WANG ,  Yingcai WANG ,  Xuelei YAN ,  Ming YU ,  Jiang ZHU

Inventor： Michael David BARTBERGER ,  Ana GONZALEZ BUENROSTRO ,  Hilary Plake BECK ,  Xiaoqi CHEN ,  Richard Victor CONNORS ,  Jeffrey DEIGNAN ,  Jason DUQUETTE ,  John EKSTEROWICZ ,  Benjamin FISHER ,  Brian Matthew FOX ,  Jiasheng FU ,  Zice FU ,  Felix GONZALEZ LOPEZ DE TURISO ,  Michael GRIBBLE, JR. ,  Darin James GUSTIN ,  Julie Anne HEATH ,  Xin HUANG ,  Xianyun JIAO ,  Michael G. JOHNSON ,  Frank KAYSER ,  David John KOPECKY ,  Sujen LAI ,  Yihong LI ,  Zhihong LI ,  Jiwen LIU ,  Jonathan Dante LOW ,  Brian Stuart LUCAS ,  Zhihua MA ,  Lawrence McGEE ,  Joel McINTOSH ,  Dustin McMINN ,  Julio Cesar MEDINA ,  Jeffrey Thomas MIHALIC ,  Steven Howard Olson ,  Yosup REW ,  Philip Marley ROVETO ,  Daqing SUN ,  Xiaodong WANG ,  Yingcai WANG ,  Xuelei YAN ,  Ming YU ,  Jiang ZHU

IPC: A61K31/451 ,  C07D413/06 ,  A61K31/5377 ,  C07D401/06 ,  A61K31/454 ,  C07D417/06 ,  A61K31/541 ,  A61K31/4545 ,  C07D413/12 ,  C07D471/10 ,  A61K31/438 ,  C07D409/04 ,  A61K31/4535 ,  A61K31/496 ,  C07D279/02 ,  C07D498/08 ,  A61K31/5386 ,  A61K31/549 ,  C07D498/16 ,  A61K31/437 ,  A61P35/00 ,  C07D211/40

CPC classification number: C07D211/76 ,  C07D221/20 ,  C07D279/02 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D407/04 ,  C07D407/06 ,  C07D409/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D491/08 ,  C07D491/153 ,  C07D498/08 ,  C07D498/14 ,  C07D498/20

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract translation: 本发明提供了式I的MDM2抑制剂化合物，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。

公开(公告)号：US08084479B2

公开(公告)日：2011-12-27

申请号：US12378195

申请日：2009-02-11

Applicant: Qingping Zeng ,  John G. Allen ,  Matthew P. Bourbeau ,  Celia Dominguez ,  Christopher H. Fotsch ,  Nianhe Han ,  Fang-Tsao Hong ,  Xin Huang ,  Matthew R. Lee ,  Aiwen Li ,  Qingyian Liu ,  James T. Rider ,  Seifu Tadesse ,  Andrew S. Tasker ,  Vellarkad N. Viswanadhan ,  Xianghong Wang ,  Kurt E. Weiler ,  George E. Wohlhieter ,  Guomin Yao ,  Chester Chenguang Yuan

Inventor： Qingping Zeng ,  John G. Allen ,  Matthew P. Bourbeau ,  Celia Dominguez ,  Christopher H. Fotsch ,  Nianhe Han ,  Fang-Tsao Hong ,  Xin Huang ,  Matthew R. Lee ,  Aiwen Li ,  Qingyian Liu ,  James T. Rider ,  Seifu Tadesse ,  Andrew S. Tasker ,  Vellarkad N. Viswanadhan ,  Xianghong Wang ,  Kurt E. Weiler ,  George E. Wohlhieter ,  Guomin Yao ,  Chester Chenguang Yuan

IPC: A01N43/38 ,  A01N43/78 ,  A61K31/405 ,  A61K31/425 ,  C07D277/00

CPC classification number: C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.

Abstract translation: 本发明涉及使用式I和式II的噻唑化合物及其组合物用于治疗由蛋白激酶B（PKB）介导的疾病，例如癌症和其它增殖性疾病，其中变量具有本文提供的定义。

公开(公告)号：US07795392B2

公开(公告)日：2010-09-14

申请号：US11804103

申请日：2007-05-17

Applicant: Todd G. Kirchgessner ,  Bonnie Hsiang ,  Yingjie Zhu ,  Yuli Wu ,  Zhaoqing Wang ,  Jean S. Lynch ,  Xin Huang ,  Wen-Pin Yang

Inventor： Todd G. Kirchgessner ,  Bonnie Hsiang ,  Yingjie Zhu ,  Yuli Wu ,  Zhaoqing Wang ,  Jean S. Lynch ,  Xin Huang ,  Wen-Pin Yang

IPC: C07K1/00 ,  C07K14/00 ,  C12P21/06 ,  C12P21/04

CPC classification number: G01N33/6872 ,  C07K14/47 ,  C07K14/705 ,  G01N2500/04

Abstract: The current invention discloses nucleic acid and amino acid sequences for novel organic anion transfer proteins (“OATPs”). The invention encompasses the OATPs described herein, together with vectors containing the cDNA sequences, host cells containing the vectors and polypeptides having all or part of an OATP. Also encompasses are uses for OATPs for targeting drugs to specific organs and for modulating the concentration of endogenous substrates.

Abstract translation: 本发明公开了新型有机阴离子转移蛋白（“OATPs”）的核酸和氨基酸序列。 本发明包括本文所述的OATP以及含有cDNA序列的载体，含有载体的宿主细胞和具有全部或部分OATP的多肽。 还包括OATPs用于将药物靶向特定器官和调节内源底物浓度的用途。

公开(公告)号：US20100085353A1

公开(公告)日：2010-04-08

申请号：US12245709

申请日：2008-10-04

Applicant: Kun Zhou ,  Xin Huang ,  Baining Guo

Inventor： Kun Zhou ,  Xin Huang ,  Baining Guo

IPC: G06T15/00

CPC classification number: G06T17/005 ,  G06T17/00 ,  G06T2210/52

Abstract: Described is a technology by which a user interacts with a surface representative of a point cloud data to correct for imperfect scan data. The surface is reconstructed based on the interaction. Real time viewing of the image is facilitated by parallel surface reconstruction. For example, the user may draw strokes to reduce topological ambiguities in poorly-sampled areas. An algorithm automatically adds new oriented sample points to the original point cloud based on the user interaction. Then a new isosurface is generated for the augmented point cloud. The user also may specify the geometry of missing areas of the surface. The user copies a set of points from another point cloud, and places the points around the target area. A new isosurface is then generated.

Abstract translation: 描述了用户与表示点云数据的表面进行交互以校正不完美扫描数据的技术。 基于交互重建表面。 通过平行表面重建，实现了图像的实时观察。 例如，用户可以绘制笔画以减少不良采样区域的拓扑模糊。 基于用户交互，算法会自动将新的定向采样点添加到原始点云。 然后为增强点云生成一个新的等值面。 用户还可以指定表面缺失区域的几何形状。 用户从另一个点云复制一组点，并将点放在目标区域周围。 然后生成新的等值面。